Effective termination of status epilepticus by rational polypharmacy in the lithium-pilocarpine model in rats: Window of opportunity to prevent epilepsy and prediction of epilepsy by biomarkers

Neurobiology of Disease

Volumn 75, Issue , 2015, Pages 78-90

  Brandt, Claudia ^a,b   Töllner, Kathrin ^a,b   Klee, Rebecca ^a,b   Bröer, Sonja ^a,b   Löscher, Wolfgang ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Biomarkers; Diazepam; Pharmacoresistance; Phenobarbital; Scopolamine

Indexed keywords

DIAZEPAM; LITHIUM; PHENOBARBITAL; PILOCARPINE; SCOPOLAMINE; ANTICONVULSIVE AGENT; LITHIUM CHLORIDE; SCOPOLAMINE BROMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CELL LOSS; CONTROLLED STUDY; DENTATE HILUS; DISEASE SEVERITY; DRUG EFFICACY; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; FEMALE; HIPPOCAMPAL CA1 REGION; NERVE DEGENERATION; NONHUMAN; POLYPHARMACY; RAT; RECURRENT DISEASE; SEIZURE THRESHOLD; ANIMAL; DISEASE MODEL; DRUG EFFECTS; ELECTRODE IMPLANT; HIPPOCAMPUS; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SEIZURES; SPRAGUE DAWLEY RAT; STATUS EPILEPTICUS; TIME; TREATMENT OUTCOME;

ANIMALS; ANTICONVULSANTS; DIAZEPAM; DISEASE MODELS, ANIMAL; ELECTRODES, IMPLANTED; ELECTROENCEPHALOGRAPHY; FEMALE; HIPPOCAMPUS; LITHIUM CHLORIDE; NEURONS; PHENOBARBITAL; PILOCARPINE; POLYPHARMACY; RATS, SPRAGUE-DAWLEY; SCOPOLAMINE HYDROBROMIDE; SEIZURES; STATUS EPILEPTICUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84921044772     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2014.12.015     Document Type: Article

References (89)

1. Adams B., Vaccarella L., Fahnestock M., Racine R.J. The cholinergic system modulates kindling and kindling-induced mossy fiber sprouting. Synapse 2002, 44:132-138.
2. Arnold P.S., Racine R.J., Wise R.A. Effects of atropine, reserpine, 6-hydroxydopamine, and handling on seizure development in the rat. Exp. Neurol. 1973, 40:457-470.
3. Bankstahl J.P., Löscher W. Resistance to antiepileptic drugs and expression of P-glycoprotein in two rat models of status epilepticus. Epilepsy Res. 2008, 82:70-85.
4. Bankstahl M., Bankstahl J.P., Löscher W. Inter-individual variation in the anticonvulsant effect of phenobarbital in the pilocarpine rat model of temporal lobe epilepsy. Exp. Neurol. 2012, 234:70-84.
5. Blümcke I., Beck H., Lie A.A., Wiestler O.D. Molecular neuropathology of human mesial temporal lobe epilepsy. Epilepsy Res. 1999, 36:205-223.
6. Bolkvadze T., Pitkanen A. Development of post-traumatic epilepsy after controlled cortical impact and lateral fluid-percussion-induced brain injury in the mouse. J. Neurotrauma 2012, 29:789-812.
7. Bradford H.F., Peterson D.W. Current views of the pathobiochemistry of epilepsy. Mol. Aspects Med. 1987, 9:119-172.
8. Brandt C., Nozadze M., Heuchert N., Rattka M., Löscher W. Disease-modifying effects of phenobarbital and the NKCC1 inhibitor bumetanide in the pilocarpine model of temporal lobe epilepsy. J. Neurosci. 2010, 30:8602-8612.
9. Brima T., Otahal J., Mares P. Increased susceptibility to pentetrazol-induced seizures in developing rats after cortical photothrombotic ischemic stroke at P7. Brain Res. 2013, 1507:146-153.
10. Bröer S., Backofen-Wehrhahn B., Bankstahl M., Gey L., Gernert M., Löscher W. Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model. Neurobiol. Dis. 2012, 46:362-376.
11. Bröer S., Zolkowska D., Gernert M., Rogawski M.A. Proconvulsant actions of intrahippocampal botulinum neurotoxin B in the rat. Neuroscience 2013, 252:253-261.
12. Brophy G.M., Bell R., Claassen J., Alldredge B., Bleck T.P., Glauser T., Laroche S.M., Riviello J.J., Shutter L., Sperling M.R., Treiman D.M., Vespa P.M. Guidelines for the evaluation and management of status epilepticus. Neurocrit. Care. 2012, 17:3-23.
13. Buterbaugh G.G., Michelson H.B., Keyser D.O. Status epilepticus facilitated by pilocarpine in amygdala-kindled rats. Exp. Neurol. 1986, 94:91-102.
14. Cain D.P., McKitrick D.J., Desborough K.A. Effects of treatment with scopolamine and naloxone, singly and in combination, on amygdala kindling. Exp. Neurol. 1987, 96:97-103.
15. Cavalheiro E.A., Leite J.P., Bortolotto Z.A., Turski W.A., Ikonomidou C., Turski L. Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia 1991, 32:778-782.
16. Chen J.W., Wasterlain C.G. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006, 5:246-256.
17. Chu K., Jung K.H., Lee S.T., Kim J.H., Kang K.M., Kim H.K., Lim J.S., Park H.K., Kim M., Lee S.K., Roh J.K. Erythropoietin reduces epileptogenic processes following status epilepticus. Epilepsia 2008, 49:1723-1732.
18. Clifford D.B., Olney J.W., Maniotis A., Collins R.C., Zorumski C.F. The functional anatomy and pathology of lithium-pilocarpine and high-dose pilocarpine seizures. Neuroscience 1987, 23:953-968.
19. Curia G., Longo D., Biagini G., Jones R.S., Avoli M. The pilocarpine model of temporal lobe epilepsy. J. Neurosci. Methods 2008, 172:143-157.
20. Dudek F.E., Sutula T.P. Epileptogenesis in the dentate gyrus: a critical perspective. Prog. Brain Res. 2007, 163:755-773.
21. Dulac O., Nabbout R., Plouin P., Chiron C., Scheffer I.E. Early seizures: causal events or predisposition to adult epilepsy?. Lancet Neurol. 2007, 6:643-651.
22. Engel J., Pitkanen A., Loeb J.A., Dudek F.E., Bertram E.H., Cole A.J., Moshe S.L., Wiebe S., Jensen F.E., Mody I., Nehlig A., Vezzani A. Epilepsy biomarkers. Epilepsia 2013, 54(Suppl. 4):61-69.
23. Francois J., Koning E., Ferrandon A., Nehlig A. The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res. 2006, 72:147-163.
24. Friedman A., Behrens C.J., Heinemann U. Cholinergic dysfunction in temporal lobe epilepsy. Epilepsia 2007, 48(Suppl. 5):126-130.
25. George B., Kulkarni S.K. Protective effects of GABAergic drugs and other anticonvulsants in lithium-pilocarpine-induced status epilepticus. Methods Find. Exp. Clin. Pharmacol. 1996, 18:335-340.
26. Glien M., Brandt C., Potschka H., Voigt H., Ebert U., Löscher W. Repeated low-dose treatment of rats with pilocarpine: low mortality but high proportion of rats developing epilepsy. Epilepsy Res. 2001, 46:111-119.
27. Hasson H., Kim M., Moshe S.L. Effective treatments of prolonged status epilepticus in developing rats. Epilepsy Behav. 2008, 13:62-69.
28. Janigro D. Are you in or out? Leukocyte, ion, and neurotransmitter permeability across the epileptic blood-brain barrier. Epilepsia 2012, 53(Suppl. 1):26-34.
29. Janigro D., Iffland P.H., Marchi N., Granata T. A role for inflammation in status epilepticus is revealed by a review of current therapeutic approaches. Epilepsia 2013, 54(Suppl. 6):30-32.
30. Jones D.M., Esmaeil N., Maren S., Macdonald R.L. Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res. 2002, 50:301-312.
31. Jope R.S., Morrisett R.A., Snead O.C. Characterization of lithium potentiation of pilocarpine-induced status epilepticus in rats. Exp. Neurol. 1986, 91:471-480.
32. Jung K.H., Chu K., Lee S.T., Kim J., Sinn D.I., Kim J.M., Park D.K., Lee J.J., Kim S.U., Kim M., Lee S.K., Roh J.K. Cyclooxygenase-2 inhibitor, celecoxib, inhibits the altered hippocampal neurogenesis with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Neurobiol. Dis. 2006, 23:237-246.
33. Jung S., Jones T.D., Lugo J.N., Sheerin A.H., Miller J.W., D'Ambrosio R., Anderson A.E., Poolos N.P. Progressive dendritic HCN channelopathy during epileptogenesis in the rat pilocarpine model of epilepsy. J. Neurosci. 2007, 27:13012-13021.
34. Kendirli M.T., Rose D.T., Bertram E.H. A Model of Posttraumatic Epilepsy after Penetrating Brain Injuries: Effect of Lesion Size and Metal Fragments 2014, Epilepsia.
35. Kharatishvili I., Pitkanen A. Association of the severity of cortical damage with the occurrence of spontaneous seizures and hyperexcitability in an animal model of posttraumatic epilepsy. Epilepsy Res. 2010, 90:47-59.
36. Klitgaard H., Matagne A., Vanneste-Goemaere J., Margineanu D.G. Pilocarpine-induced epileptogenesis in the rat: impact of initial duration of status epilepticus on electrophysiological and neuropathological alterations. Epilepsy Res. 2002, 51:93-107.
37. Kücker S., Töllner K., Piechotta M., Gernert M. Kindling as a model of temporal lobe epilepsy induces bilateral changes in spontaneous striatal activity. Neurobiol. Dis. 2010, 37:661-672.
38. Langer M., Brandt C., Zellinger C., Löscher W. Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology 2011, 61:1033-1047.
39. Lee M.G., Chou J.Y., Lee K.H., Choi B.J., Kim S.K., Kim C.Y. MK-801 augments pilocarpine-induced electrographic seizure but protects against brain damage in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 1997, 21:331-344.
40. Leite J.P., Garcia-Cairasco N., Cavalheiro E.A. New insights from the use of pilocarpine and kainate models. Epilepsy Res. 2002, 50:93-103.
41. Lemos T., Cavalheiro E.A. Suppression of pilocarpine-induced status epilepticus and the late development of epilepsy in rats. Exp. Brain Res. 1995, 102:423-428.
42. Libbey J.E., Fujinami R.S. Neurotropic viral infections leading to epilepsy: focus on Theiler's murine encephalomyelitis virus. Futur. Virol. 2011, 6:1339-1350.
43. Löscher W. Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res. 2002, 50:105-123.
44. Löscher W. The pharmacokinetics of antiepileptic drugs in rats: consequences for maintaining effective drug levels during prolonged drug administration in rat models of epilepsy. Epilepsia 2007, 48:1245-1258.
45. Löscher W. Molecular mechanisms of drug resistance in status epilepticus. Epilepsia 2009, 50(Suppl. 12):19-21.
46. Löscher W. Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur. J. Pharmacol. 2009, 610:1-11.
47. Löscher W., Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol. Rev. 2010, 62:668-700.
48. Lowenstein D.H. Epilepsy after head injury: an overview. Epilepsia 2009, 50(Suppl. 2):4-9.
49. Marchi N., Oby E., Batra A., Uva L., De Curtis M., Hernandez N., Boxel-Dezaire A., Najm I., Janigro D. In vivo and in vitro effects of pilocarpine: relevance to ictogenesis. Epilepsia 2007, 48:1934-1946.
50. Marchi N., Fan Q., Ghosh C., Fazio V., Bertolini F., Betto G., Batra A., Carlton E., Najm I., Granata T., Janigro D. Antagonism of peripheral inflammation reduces the severity of status epilepticus. Neurobiol. Dis. 2009, 33:171-181.
51. Mazzuferi M., Kumar G., Rospo C., Kaminski R.M. Rapid epileptogenesis in the mouse pilocarpine model: video-EEG, pharmacokinetic and histopathological characterization. Exp. Neurol. 2012, 238:156-167.
52. McGeer E.G., McGeer P.L. Substantia nigra cell death from kainic acid or folic acid injections into the pontine tegmentum. Brain Res. 1984, 298:339-342.
53. Menon B., Shorvon S.D. Ischaemic stroke in adults and epilepsy. Epilepsy Res. 2009, 87:1-11.
54. Mishra A.M., Bai X., Sanganahalli B.G., Waxman S.G., Shatillo O., Grohn O., Hyder F., Pitkanen A., Blumenfeld H. Decreased resting functional connectivity after traumatic brain injury in the rat. PLoS One 2014, 9:e95280.
55. Morrisett R.A., Jope R.S., Snead O.C. Effects of drugs on the initiation and maintenance of status epilepticus induced by administration of pilocarpine to lithium-pretreated rats. Exp. Neurol. 1987, 97:193-200.
56. Nehlig A. What is animal experimentation telling us about new drug treatments of status epilepticus?. Epilepsia 2007, 48(Suppl. 8):78-81.
57. Olsen R.W. GABA-drug interactions. Prog. Drug Res. 1987, 31:223-241.
58. Omori Y., Endo T., Hara Y., Nishiyama M., Midgley I., Smart C.I., John A.J., Chasseaud L.F., McBurney A., John B.A. Absorption, distribution and excretion of 14C-pilocarpine following oral administration to rats. Arzneimittelforschung 2004, 54:171-178.
59. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Elsevier, Amsterdam. 6th ed.
60. Pereira H.A., Benassi S.K., Mello L.E. Plastic changes and disease-modifying effects of scopolamine in the pilocarpine model of epilepsy in rats. Epilepsia 2005, 46(Suppl. 5):118-124.
61. Pitkänen A. Efficacy of current antiepileptics to prevent neurodegeneration in epilepsy models. Epilepsy Res. 2002, 50:141-160.
62. Pitkänen A. New pharmacotherapy for epilepsy. Indian Drugs 2004, 7:471-477.
63. Pitkänen A., Wasterlain C.C. Commentary: translation of laboratory findings to clinic in the treatment of status epilepticus-a mission impossible?. Epilepsia 2009, 50:1834-1835.
64. Pitkänen A., Nissinen J., Nairismagi J., Lukasiuk K., Grohn O.H., Miettinen R., Kauppinen R. Progression of neuronal damage after status epilepticus and during spontaneous seizures in a rat model of temporal lobe epilepsy. Prog. Brain Res. 2002, 135:67-83.
65. Pitkänen A., Immonen R.J., Grohn O.H., Kharatishvili I. From traumatic brain injury to posttraumatic epilepsy: what animal models tell us about the process and treatment options. Epilepsia 2009, 50(Suppl. 2):21-29.
66. Pitkänen A., Nehlig A., Brooks-Kayal A.R., Dudek F.E., Friedman D., Galanopoulou A.S., Jensen F.E., Kaminski R.M., Kapur J., Klitgaard H., Löscher W., Mody I., Schmidt D. Issues related to development of antiepileptogenic therapies. Epilepsia 2013, 54(Suppl. 4):35-43.
67. Polascheck N., Bankstahl M., Löscher W. The COX-2 inhibitor parecoxib is neuroprotective but not antiepileptogenic in the pilocarpine model of temporal lobe epilepsy. Exp. Neurol. 2010, 224:219-233.
68. Prasad A., Williamson J.M., Bertram E.H. Phenobarbital and MK-801, but not phenytoin, improve the long-term outcome of status epilepticus. Ann. Neurol. 2002, 51:175-181.
69. Rattka M., Brandt C., Bankstahl M., Bröer S., Löscher W. Enhanced susceptibility to the GABA antagonist pentylenetetrazole during the latent period following a pilocarpine-induced status epilepticus in rats. Neuropharmacology 2011, 60:505-512.
70. Reddy D.S., Kuruba R. Experimental models of status epilepticus and neuronal injury for evaluation of therapeutic interventions. Int. J. Mol. Sci. 2013, 14:18284-18318.
71. Rice A.C., DeLorenzo R.J. NMDA receptor activation during status epilepticus is required for the development of epilepsy. Brain Res. 1998, 782:240-247.
72. Rigoulot M.A., Koning E., Ferrandon A., Nehlig A. Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy. J. Pharmacol. Exp. Ther. 2004, 308:787-795.
73. Rossetti A.O., Lowenstein D.H. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol. 2011, 10:922-930.
74. Scorza F.A., Arida R.M., Naffah-Mazzacoratti M.G., Scerni D.A., Calderazzo L., Cavalheiro E.A. The pilocarpine model of epilepsy: what have we learned?. An. Acad. Bras. Cienc. 2009, 81:345-365.
75. Scott R.C. What are the effects of prolonged seizures in the brain?. Epileptic. Disord. 2014, 16(Suppl. 1):6-11.
76. Sirven J.I. Not all first seizures are created equally. Epilepsy Curr. 2009, 9:164-165.
77. Sloviter R.S. Decreased hippocampal inhibition and a selective loss of interneurons in experimental epilepsy. Science 1987, 235:73-76.
78. Sloviter R.S. The functional organization of the hippocampal dentate gyrus and its relevance to the pathogenesis of temporal lobe epilepsy. Ann. Neurol. 1994, 35:640-654.
79. Sloviter R.S. Hippocampal pathology and pathophysiology in temporal lobe epilepsy. Neurologia 1996, 11(Suppl. 4):29-32.
80. So N., Gloor P., Quesney L.F., Jones-Gotman M., Olivier A., Andermann F. Depth electrode investigations in patients with bitemporal epileptiform abnormalities. Ann. Neurol. 1989, 25:423-431.
81. Sobotka T.J., Brown R., Quander D.Y., Jackson R., Smith M., Long S.A., Barton C.N., Rountree R.L., Hall S., Eilers P., Johannessen J.N., Scallet A.C. Domoic acid: neurobehavioral and neurohistological effects of low-dose exposure in adult rats. Neurotoxicol. Teratol. 1996, 18:659-670.
82. Steinlein O.K., Bertrand D. Nicotinic receptor channelopathies and epilepsy. Pflugers Arch. 2010, 460:495-503.
83. Thom M., Martinian L., Catarino C., Yogarajah M., Koepp M.J., Caboclo L., Sisodiya S.M. Bilateral reorganization of the dentate gyrus in hippocampal sclerosis: a postmortem study. Neurology 2009, 73:1033-1040.
84. Turski W.A., Cavalheiro E.A., Schwarz M., Czuczwar S.J., Kleinrok Z., Turski L. Limbic seizures produced by pilocarpine in rats: behavioural, electroencephalographic and neuropathological study. Behav. Brain Res. 1983, 9:315-335.
85. Turski L., Ikonomidou C., Turski W.A., Bortolotto Z.A., Cavalheiro E.A. Review: cholinergic mechanisms and epileptogenesis. The seizures induced by pilocarpine: a novel model of intractable epilepsy. Synapse 1989, 3:154-171.
86. Wasterlain C.G., Chen J.W. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia 2008, 49(Suppl. 9):63-73.
87. Wasterlain C.G., Fujikawa D.G., Penix L., Sankar R. Pathophysiological mechanisms of brain damage from status epilepticus. Epilepsia 1993, 34(Suppl. 1):S37-S53.
88. Wasterlain C.G., Liu H., Naylor D.E., Thompson K.W., Suchomelova L., Niquet J., Mazarati A.M., Baldwin R.A. Molecular basis of self-sustaining seizures and pharmacoresistance during status epilepticus: the receptor trafficking hypothesis revisited. Epilepsia 2009, 50(Suppl. 12):16-18.
89. Westerberg V., Corcoran M.E. Antagonism of central but not peripheral cholinergic receptors retards amygdala kindling in rats. Exp. Neurol. 1987, 95:194-206.